Articles published by Lexaria Bioscience Corp.
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
Lexaria Provides Annual Letter From the CEO
January 27, 2022
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
November 03, 2021
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 13, 2021
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
October 05, 2021
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
Lexaria Receives US$3,817,643 From Warrant Exercises
July 26, 2021
Lexaria Receives Patent Protection in Japan
July 13, 2021
Lexaria Announces 2021 Annual Meeting Results
June 29, 2021